ABBV Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

222.380

Open

221.370

VWAP

218.08

Vol

9.65M

Mkt Cap

382.49B

Low

215.370

Amount

2.10B

EV/EBITDA(TTM)

15.11

Total Shares

1.77B

454.38B

EV/OCF(TTM)

21.41

P/S(TTM)

6.24

AbbVie Inc. is a global, diversified, research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. The aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Duodopa is a levodopa-carbidopa intestinal gel for the treatment of Parkinson's disease. Eye care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella.

Events Timeline

(ET)

2026-06-16

08:30:00

Allergan Aesthetics Receives FDA Approval for Skinvive

2026-06-12 (ET)

2026-06-12

05:30:00

AbbVie Announces New Data on Chronic Lymphocytic Leukemia

2026-05-29 (ET)

2026-05-29

08:40:00

AbbVie’s Venclyxto Receives Expanded Indication from EU

2026-05-27 (ET)

2026-05-27

18:30:00

AbbVie’s DECNUPAZ Approved by FDA for BPDCN Treatment

2026-05-27

15:30:00

AbbVie Receives FDA Approval for Decnupaz in Adults

2026-05-22 (ET)

2026-05-22

08:10:00

AbbVie’s Maviret Receives Positive Opinion from EU Medicines Agency

2026-05-21 (ET)

2026-05-21

16:20:00

Allergan Aesthetics Receives Positive Opinion from EMA

News

8.5

06-16NASDAQ.COM

PinnedSKINVIVE by JUVÉDERM Receives FDA Approval for Neck Treatment

8.0

06-18PRnewswire

AbbVie Declares Quarterly Cash Dividend of $1.73

4.5

06-18NASDAQ.COM

IWF Stock Price Analysis and ETF Dynamics

5.0

06-16seekingalpha

AbbVie Receives FDA Approval for New Neck Anti-Wrinkle Product

9.0

06-16NASDAQ.COM

FDA Approves SKINVIVE by JUVÉDERM for Neck Wrinkles

8.5

06-16PRnewswire

Conexeu Sciences Expands Board to Support Commercialization Efforts

18 Analyst Rating

Wall Street analysts forecast ABBV stock price to rise

12 Buy

6 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

223.00

Averages

252.00

High

289.00

Current: 0.000

Low

223.00

Averages

252.00

High

289.00

Evercore ISI

NULL

Outperform

maintain

$236 -> $235

AI Analysis

2026-05-15

Reason

Evercore ISI

Price Target

$236 -> $235

AI Analysis

2026-05-15

maintain

NULL

Outperform

Reason

Evercore ISI lowered the firm's price target on AbbVie to $235 from $236 and keeps an Outperform rating on the shares.

Piper Sandler

Overweight

maintain

$294 -> $298

2026-05-14

Reason

Piper Sandler

Price Target

$294 -> $298

2026-05-14

maintain

Overweight

Reason

Piper Sandler raised the firm's price target on AbbVie to $298 from $294 and keeps an Overweight rating on the shares. The depth of AbbVie's inflammatory bowel disease pipeline remains the focus of significant investor attention, the firm says. Given the white-hot nature of the IBD drug development landscape, management's advancement of novel combination approaches in IBD is undoubtedly a welcome development. That said, one of the considerations that renders AbbVie shares attractive in Piper's view is the range of R&D shots-on-goal that continue to fall under the broader investor radar.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ABBV

Unlock Now

Valuation Metrics

The current forward P/E ratio for Abbvie Inc (ABBV.N) is 15.60, compared to its 5-year average forward P/E of 13.63. For a more detailed relative valuation and DCF analysis to assess Abbvie Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

13.63

Current PE

15.60

Overvalued PE

16.31

Undervalued PE

10.96

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

12.92

Current EV/EBITDA

14.53

Overvalued EV/EBITDA

15.96

Undervalued EV/EBITDA

9.87

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

5.02

Current PS

5.41

Overvalued PS

5.78

Undervalued PS

4.26

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

Elite pharma

Intellectia · 9 candidates

Sector: Healthcare, Healthcare Services & Equipment, Pharmaceuticals & Medical ResearchIndustry: Biotechnology & Medical Research, PharmaceuticalsPrice: >= $-100.00Volume: >= -100Themes: Medical Instruments & Supplies, Genomics, Cancer Research, BiotechRsi Category: moderateMoving Average Relationship: PriceAboveMA20, PriceAboveMA200Ema 20: >= -100Ema 60: >= -100Weekly Average Dollar Volume: >= -100

Ticker

Name

Market Cap$

JNJ

Johnson & Johnson

570.51B

ABBV

AbbVie Inc

398.27B

MRK

Merck & Co Inc

295.39B

AMGN

Amgen Inc

185.96B

VRTX

Vertex Pharmaceuticals Inc

113.14B

BIIB

Biogen Inc

29.39B

Mega Cap Stocks Bullish for a Month

Intellectia · 22 candidates

Market Cap Category: megaMoving Average Relationship: PriceAboveMA20One Month Rise Prob: >= 50One Month Predict Return: >= 0.0%Macd: bullish

Ticker

Name

Market Cap$

Micron Technology Inc

1.22T

CSCO

Cisco Systems Inc

498.59B

IBM

International Business Machines Corp

287.26B

AMD

Advanced Micro Devices Inc

884.63B

ORCL

Oracle Corp

662.44B

KLAC

KLA Corp

277.60B

new IPO to buy

Intellectia · 21 candidates

Market Cap: >= 500.00MRegion: USVolume: >= 500,000Analyst Consensus: Strong Buy, Moderate Buy, HoldRsi Category: moderateList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20, PriceAboveMA200Month Price Change Pct: >= $0.00Is Trending: True

Ticker

Name

Market Cap$

LLY

Eli Lilly and Co

1000.00B

LRCX

Lam Research Corp

403.53B

ABBV

AbbVie Inc

376.54B

General Electric Co

328.12B

GLW

Corning Inc

168.83B

General Dynamics Corp

93.20B

stocks up in a down market

Intellectia · 87 candidates

Relative Vol: >= 1.50Moving Average Relationship: PriceAboveMA20, PriceAboveMA200Week Price Change Pct: >= $0.00Month Price Change Pct: >= $0.00Is Index Component: GSPCEma 20: >= 0Macd: bullish

Ticker

Name

Market Cap$

AAPL

Apple Inc

4.39T

WMT

Walmart Inc

1.07T

XOM

Exxon Mobil Corp

673.76B

Visa Inc

625.00B

COST

Costco Wholesale Corp

485.50B

CSCO

Cisco Systems Inc

455.74B

which megacap surged max yesterday

Intellectia · 64 candidates

Region: USMarket Cap Category: mega

Ticker

Name

Market Cap$

UNH

UnitedHealth Group Inc

359.98B

Philip Morris International Inc

291.34B

NFLX

Netflix Inc

369.12B

ABBV

AbbVie Inc

367.25B

LLY

Eli Lilly and Co

932.20B

COST

Costco Wholesale Corp

453.36B

what stock earnings next week

Intellectia · 133 candidates

Market Cap: >= 10.00BPrice: >= $10.00Is Index Component: GSPCMonthly Average Dollar Volume: >= 1,000,000

Ticker

Name

Market Cap$

GOOG

Alphabet Inc

4.09T

MSFT

Microsoft Corp

3.09T

AMZN

Amazon.com Inc

2.74T

Whales Holding ABBV

The Glenmede Trust Company, National Association

ARS Investment Partners, LLC

Pallas Capital Advisors LLC

Nomura Asset Management Taiwan Ltd.

Texas Yale Capital Corp.

Trading Trends

People Also Watch

Frequently Asked Questions

What is Abbvie Inc (ABBV) stock price today?

The current price of ABBV is 216.49 USD — it has decreased -2.14

What is Abbvie Inc (ABBV)'s business?

What is the price predicton of ABBV Stock?

Wall Street analysts forecast ABBV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABBV is252.00 USD with a low forecast of 223.00 USD and a high forecast of 289.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Abbvie Inc (ABBV)'s revenue for the last quarter?

Abbvie Inc revenue for the last quarter amounts to 15.00B USD, increased 12.43

What is Abbvie Inc (ABBV)'s earnings per share (EPS) for the last quarter?

Abbvie Inc. EPS for the last quarter amounts to 0.39 USD, decreased -45.83

How many employees does Abbvie Inc (ABBV). have?

Abbvie Inc (ABBV) has 57000 emplpoyees as of June 19 2026.

What is Abbvie Inc (ABBV) market cap?

Today ABBV has the market capitalization of 382.49B USD.

ABBV Overview

ABBV Overview

Events Timeline

News

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Related Community Screener

Whales Holding ABBV

Trading Trends

People Also Watch

Frequently Asked Questions

What is Abbvie Inc (ABBV) stock price today?

What is Abbvie Inc (ABBV)'s business?

What is the price predicton of ABBV Stock?

What is Abbvie Inc (ABBV)'s revenue for the last quarter?

What is Abbvie Inc (ABBV)'s earnings per share (EPS) for the last quarter?

How many employees does Abbvie Inc (ABBV). have?

What is Abbvie Inc (ABBV) market cap?